NewsRoom Articles - Page 89 of 214

FridayDec 16, 2022 12:00 pm

Jupiter Wellness Inc. (NASDAQ: JUPW) Is ‘One to Watch’

Jupiter Wellness’s product pipeline addresses a range of underserved conditions, including hair loss, eczema, burns, and sexual wellness The company’s revenue is generated through OTC and consumer product sales, contract research agreements, and licensing royalties Jupiter Wellness recently announced that it has been approved to dual list its shares on Upstream, the revolutionary trading app for digital securities and NFTs Jupiter Wellness (NASDAQ: JUPW) is a diversified company that supports health and wellness by researching and developing over-the-counter (“OTC”) products and intellectual property. The company has a robust and growing portfolio of granted and pending patents to protect its proprietary…

FridayDec 16, 2022 11:15 am

MetAlert, Inc. (MLRT) Going into 2023 in a Much Healthier Position after Eliminating All Toxic Debt in Q4 2022 and Launching New Remote Patient Monitoring Medical Devices

Ludlow Research ups price target for MetAlert, leading developer of location-sensitive health monitoring devices and wearable technology products, anticipating target between $1 and $1.25 per share MetAlert announced the elimination of all its toxic convertible notes from its balance sheet, which now provides increased stability to its public float The company also shared improved guidance to its NFC operations while also announcing the launch of new medical devices geared toward the geriatric and autism healthcare markets Q4 2022 also saw the influx of new chips, which will significantly increase production of the company’s SmartSole units in early 2023, ramp up…

ThursdayDec 15, 2022 1:37 pm

Research Links Diets High in Fat to Chronic Pain

Diets are important to individuals’ health, with what a person consumes influencing their body by either strengthening their immune system or increasing their risk of developing lifestyle diseases. New research has found that diets high in fat may increase an individual’s sensitivity to nonpainful stimuli, causing chronic pain. It is normally recommended for individuals to consume fat in order to ensure that their bodies function optimally. The Dietary Guidelines for Americans 2020–2025, recommend that less than 10% of calorie intake should come from saturated fats. Worth noting is the fact that consuming a lot of fat may cause various issues.…

WednesdayDec 14, 2022 12:26 pm

New Study Finds That Hearing Aids May Slow Down Cognitive Decline

New research has found that hearing aids may slow down decline in cognitive function. While prior studies have established that a loss in hearing is a risk factor in the development of dementia, it wasn’t clear if managing hearing loss would slow the progression of cognitive decline — until now. The new study, whose findings were reported in “JAMA Neurology,” provides new evidence demonstrating that hearing loss management could help decrease or even delay a decline in an individual’s cognitive function. For their study, the researchers examined the link between cognitive decline and hearing loss over different durations by conducting…

WednesdayDec 14, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Anchors Focus and Priority on Berubicin Clinical Development for GBM Treatment

John Climaco, CNS’s CEO, has lauded the company’s progress in Q3 2022, noting the successful expansion of its pivotal Berubicin trial into Europe within the quarter The company hopes to address the unmet need associated with GBM treatment with its lead drug candidate, Berubicin, trusting that the expansion into Europe will be integral to achieving interim analysis by mid-2023 CNS looks to build on the successful patient enrollment and dosing in France, which brings its operational tally to 29 of 68 clinical sites enrolling patients across the United States and Europe, as it works toward interim analysis of clinical trials…

TuesdayDec 13, 2022 12:23 pm

Psoriasis Patients Report Being Embarrassed Because of Flare-Ups in Intertriginous Areas

An analysis conducted on a 2021 poll has released results indicating that most patients suffering from plaque psoriasis have reported symptoms in intertriginous areas, which sometimes prevents them from seeking medical guidance. The researchers looked into the sexual, psychosocial and mental impact of such symptoms on the affected patients and found that roughly two-thirds of patients would like to have therapy options to treat psoriasis in these areas. A team of U.S. researchers, led by Teri Greiling, conducted the analysis of the Harris Poll’s findings and presented their results at this year’s Society of Dermatology Physician Assistants annual meeting. Greiling…

TuesdayDec 13, 2022 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Innovative Inhaled COVID-19 NanoAb Therapy Shows Statistically Significant Efficacy Results in Preclinical Study

The NanoAbs may provide improve upon existing treatments such as Paxlovid, which has several contraindications The company’s pipeline of alpaca-derived NanoAb therapies aims to address diseases with large underserved medical needs, including COVID-19, asthma, psoriasis, and more The global COVID-19 therapy market was valued at $16.8 billion in 2021 and is expected to grow at a CAGR of 20%, resulting in a value of $35.42 billion by 2025 A study recently published in JAMA Network found that nearly 15% of COVID-19 patients admitted to 36 Paris University hospitals had contraindications (excluding factors) to Paxlovid, the leading COVID-19 treatment. While Paxlovid…

MondayDec 12, 2022 12:03 pm

Data Shows Increase in Mortality Among Patients with Malignant Brain Tumors

Malignant brain tumors are fast growing and are known to spread to other areas of the brain and spine. These brain tumors are often graded based on how fast they grow and their likelihood of growing back following treatment. The most common type of malignant brain tumor are gliomas, which make up more than 75% of brain tumors. During the 27th annual meeting of the Society for Neuro-Oncology, data on the rise observed in the mortality rate of patients with primary malignant brain tumors was presented. For their research, the investigators conducted an analysis of mortality data obtained from the…

MondayDec 12, 2022 10:30 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Has Potential to Make History in Battle Against Deadly Brain Cancer with Berubicin

Glioblastoma, also known as GBM, is a fatal and incurable brain cancer that tends to recur aggressively after initial treatment CNS Pharmaceuticals is a U.S.-based pharmaceutical innovator whose flagship drug candidate, Berubicin, is a potentially pivotal treatment for treating GBM because of its novel apparent ability to cross the blood-brain barrier at effective levels CNS is building upon prior clinical trial outcomes with its global potentially pivotal trial currently registering patients in the United States and Europe Berubicin’s development is being advanced with potential time and cost savings thanks to the FDA’s decision to grant it Fast Track and Orphan…

FridayDec 09, 2022 10:33 am

Existing Drug May Alleviate Side Effects of Cancer Treatment

Cancer treatments often involve surgery, radiation and chemotherapy, which may be administered separately or conjointly, in accordance with a patient’s treatment plan. Commonly prescribed potent chemotherapy drugs include cisplatin, which was first discovered in 1965 at Michigan State University. Cisplatin has proven to be an effective chemotherapy medication that can be useful in the treatment of various solid cancers, including lung, ovarian, testicular, head and neck, bladder and stomach. However, this drug also causes many side effects, including nausea and vomiting; kidney toxicity, which may cause kidney failure in roughly 35% of patients ingesting the drug; and peripheral neuropathy, which…